<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887532</url>
  </required_header>
  <id_info>
    <org_study_id>HR19042-101</org_study_id>
    <nct_id>NCT04887532</nct_id>
  </id_info>
  <brief_title>A Trial of HR19042 Capsule in Healthy Chinese Subjects</brief_title>
  <official_title>Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule&#xD;
      after single administration in healthy Chinese subjects. To explore the pharmacokinetic&#xD;
      characteristics and safety of HR19042 capsule in healthy Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single center, open, three-period, sequential design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Peak concentration of drug observed from 0 hour to 24 hours after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t;</measure>
    <time_frame>0-24 hours</time_frame>
    <description>The area under the drug concentration-time curve at the sample collection time t that can be accurately determined from 0 hour to 24 hours after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>0 hour to 24 hours</time_frame>
    <description>The area under the concentration-time curve of drug from 0 hour to infinity after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Screening period to end of follow-up period, approximately 1 month</time_frame>
    <description>Adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of blood cortisol AUC0-24h from baseline after each cycle of administration</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Primary IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>HR19042 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR19042 capsule</intervention_name>
    <description>phase 1 :8mg; phase 2:12mg; phase 3:16mg</description>
    <arm_group_label>HR19042 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 ~ 45 years old, including boundary value;&#xD;
&#xD;
          2. Female subjects weigh ≥45kg, male subjects weigh ≥50kg, and body mass index (BMI) is&#xD;
             within the range of 19.0~26.0kg/m2 (body mass index = weight (kg)/height 2 (m2)),&#xD;
             including boundary values;&#xD;
&#xD;
          3. The subject has no plans to give birth or donate sperm/eggs for at least 3 months from&#xD;
             the signing of the informed consent form to the end of the study, and voluntarily take&#xD;
             effective non-drug contraceptive measures (including partners) during the trial&#xD;
             period;&#xD;
&#xD;
          4. Before the test, learn more about the nature, significance, possible benefits,&#xD;
             possible inconvenience and potential risks of the test. Able to understand the&#xD;
             procedures and methods of this research, willing to strictly abide by the clinical&#xD;
             trial protocol to complete the trial, and voluntarily sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. People with a known history of drug or food allergies;&#xD;
&#xD;
          2. Past or current history of any disease that may affect the safety of subjects&#xD;
             participating in the trial or the internal process of the research drug, including:&#xD;
             digestive system, blood system, circulatory system, urinary system, respiratory&#xD;
             system, nervous system, immune system, endocrine system, Those with a clear history of&#xD;
             mental disorders and metabolic disorders, or other diseases that are not suitable for&#xD;
             participating in clinical trials;&#xD;
&#xD;
          3. Those who have used drugs that affect the function of liver metabolic enzyme CYP3A4&#xD;
             within 30 days before the first administration (such as inducers-enzalutamide,&#xD;
             mitotane, carbamazepine, phenytoin, rifampin; inhibitors-clarithromycin, irradian)&#xD;
             Traconazole, ketoconazole, ritonavir, telithromycin, etc.), or those who have used&#xD;
             contraceptives within 30 days before administration;&#xD;
&#xD;
          4. Those who have used any drug within 14 days before the first dose;&#xD;
&#xD;
          5. Those who have taken a special diet (including grapefruit/grapefruit juice, chocolate,&#xD;
             food or beverages containing caffeine) within 48 hours before the first&#xD;
             administration, or have consumed excessive amounts of tea, coffee or beverages&#xD;
             containing caffeine every day for the past 1 month (Average more than 8 cups per day,&#xD;
             200 mL per cup);&#xD;
&#xD;
          6. Participate in drug clinical trials and take trial drugs as subjects within 3 months&#xD;
             before screening, or plan to participate in other clinical trials during the study&#xD;
             period;&#xD;
&#xD;
          7. Those who donated blood or lost more than 400 mL (excluding menstrual blood loss in&#xD;
             women) within 3 months before screening, received blood transfusion or used blood&#xD;
             products, or planned to donate blood during the trial period or within 1 month after&#xD;
             the end of the trial;&#xD;
&#xD;
          8. Those who have undergone major surgery within 3 months before screening, or plan to&#xD;
             undergo surgery during the study period;&#xD;
&#xD;
          9. Those who smoked more than 5 cigarettes a day on average in the 3 months before&#xD;
             screening, or who did not agree to ban smoking during the trial;&#xD;
&#xD;
         10. In the 6 months before screening, the average weekly alcohol consumption exceeded 14&#xD;
             units of alcohol (1 unit = 360 mL of beer with 5% alcohol content or 45 mL of spirits&#xD;
             with 40% alcohol content or 150 mL of wine with 12% alcohol content), Or those who do&#xD;
             not agree to abstain from alcohol during the trial;&#xD;
&#xD;
         11. The results of laboratory tests (blood routine, urine routine, blood biochemistry,&#xD;
             blood coagulation function) are judged by clinicians as abnormal and clinically&#xD;
             significant;&#xD;
&#xD;
         12. Those whose 12-lead ECG, physical examination or vital signs examination results are&#xD;
             judged by clinicians as abnormal and clinically meaningful;&#xD;
&#xD;
         13. Immunological examinations (hepatitis B surface antigen, hepatitis C virus antibody,&#xD;
             human immunodeficiency virus antibody, Treponema pallidum antibody) are positive;&#xD;
&#xD;
         14. Those with abnormal chest radiograph (posterior anterior position) and clinical&#xD;
             significance;&#xD;
&#xD;
         15. Women who are pregnant or breastfeeding;&#xD;
&#xD;
         16. Those who have a positive alcohol breath test;&#xD;
&#xD;
         17. Those who have a positive urine drug screening;&#xD;
&#xD;
         18. Those who have a history of drug abuse or drug abuse;&#xD;
&#xD;
         19. People with a history of difficulty in venous blood collection, intolerance to&#xD;
             venipuncture, or a history of fainting needles&#xD;
&#xD;
         20. Those who have difficulty swallowing, or have special dietary requirements and cannot&#xD;
             follow a uniform diet;&#xD;
&#xD;
         21. The investigator believes that the subject has any other factors that are not suitable&#xD;
             for participating in this trial (such as inability to understand the research&#xD;
             requirements, poor compliance, infirmity, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200231</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

